GCTK Stock Price, GlucoTrack, Inc. Quote, Chart

Market Summary

USD0.48-0.28

Market Closed

-36.84%

GCTK Stock Price

View Fullscreen

GCTK RSI Chart

GCTK Valuation

Market Cap

20.3M

Price/Earnings (Trailing)

-2.87

Price/Sales (Trailing)

105.48

Price/Free Cashflow

-3.1

GCTK Price/Sales (Trailing)

GCTK Profitability

Return on Equity

-221.99%

Return on Assets

-144.69%

Free Cashflow Yield

-32.25%

GCTK Fundamentals

GCTK Revenue

Revenue (TTM)

208.0K

GCTK Earnings

Earnings (TTM)

-7.1M

Earnings Growth (Yr)

-87.41%

Earnings Growth (Qtr)

-8.5%

Breaking Down GCTK Revenue

Last 7 days

46.2%

Last 30 days

130.3%

Last 90 days

245.5%

Trailing 12 Months

16.9%

How does GCTK drawdown profile look like?

GCTK Financial Health

Current Ratio

3.22

GCTK Investor Care

Shares Dilution (1Y)

72.58%

Diluted EPS (TTM)

0.96

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2020	0	0	0	0
2019	40.8K	136.1K	140.3K	208.0K
2018	562.5K	486.9K	466.0K	43.5K
2017	618.8K	327.9K	337.5K	630.5K
2016	156.5K	470.9K	482.2K	611.7K
2015	80.6K	101.5K	122.3K	143.2K
2014	0	0	0	59.8K

Get all data in R, Python etc through our Historical Stock Data APIs

Which funds bought or sold GCTK recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	Accurate Wealth Management, LLC	unchanged	-	12,595	18,120	-%
Feb 26, 2024	Virtu Financial LLC	new	-	5,000	5,000	-%
Feb 14, 2024	CITADEL ADVISORS LLC	added	19.76	1,903	10,246	-%
Feb 14, 2024	TWO SIGMA SECURITIES, LLC	reduced	-34.08	-1,821	3,484	-%
Feb 14, 2024	SABBY MANAGEMENT, LLC	reduced	-78.6	-413,951,000	112,159,000	0.11%
Feb 13, 2024	BOSTON FINANCIAL MANGEMENT LLC	reduced	-50.00	-6,949	6,897	-%
Feb 12, 2024	ALERUS FINANCIAL NA	unchanged	-	-70.00	18,116	-%
Feb 09, 2024	UBS Group AG	added	6,566	1,239	1,258	-%
Feb 07, 2024	Warberg Asset Management LLC	sold off	-100	-7,875	-	-%
Feb 07, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%

Are Funds Buying or Selling GCTK?

Are funds buying GCTK calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own GCTK

No. of Funds

Unveiling GlucoTrack, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 03, 2024	sabby management, llc	9.99%	2,087,130	SC 13G

Recent SEC filings of GlucoTrack, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 01, 2024	DEF 14A	DEF 14A
Mar 28, 2024	10-K	Annual Report
Mar 22, 2024	PRE 14A	PRE 14A
Feb 16, 2024	8-K	Current Report

Peers (Alternatives to GlucoTrack, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	185.5B	40.1B	-2.69%	-2.54%	32.41	4.63	-8.12%	-17.45%
BDX	67.5B	19.5B	-4.86%	-10.59%	53.77	3.46	4.02%	-22.04%
ALGN	23.4B	3.9B	-2.36%	-14.10%	52.63	6.06	3.42%	23.09%
BAX	20.8B	14.8B	-2.22%	-9.67%	7.83	1.4	2.12%	209.17%
MID-CAP
HSIC	9.4B	12.3B	-0.49%	-14.47%	22.48	0.76	-2.44%	-22.68%
ATR	9.3B	3.5B	-1.02%	16.40%	32.52	2.65	4.97%	18.89%
BIO	8.1B	2.7B	-18.63%	-38.25%	-12.74	3.04	-4.68%	82.43%
XRAY	6.4B	4.0B	-5.77%	-25.53%	-47.58	1.61	1.10%	85.84%
AXNX	3.4B	366.4M	-2.62%	10.65%	-558.61	9.25	33.86%	89.83%
PDCO	2.3B	6.6B	-4.73%	-4.84%	12.02	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-11.22%	-19.13%	-1.92	0.41	7.73%	-1066.14%
ANIK	383.0M	166.7M	1.30%	-3.37%	-4.63	2.3	6.67%	-456.34%
ANGO	241.5M	324.0M	12.50%	-31.24%	-1.26	0.75	-3.19%	-337.41%
APYX	45.7M	52.3M	5.60%	-56.15%	-2.44	0.87	17.61%	19.28%
AEMD	4.0M	3.7M	-11.70%	184.91%	-0.32	1.06	5.77%	8.23%

GlucoTrack, Inc. News

Latest updates

GlucoTrack, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3	2017Q2	2017Q1	2016Q4	2016Q3	2016Q2	2016Q1	2015Q4	2015Q3
Revenue	-	-	-	-	68.00	4.00	111	26.00	-	-	15.00	28.00	423	21.00	91.00	96.00	130	11.00	382	89.00	-	-
Costs and Expenses	-	-	-	-	-	-	-	-	-	-	-	-	3,143	2,669	2,657	2,696	1,451	1,498	1,965	1,354	1,555	1,123
Operating Expenses	45.2%	887	611	756	674	985	1,005	1,051	1,011	1,611	2,022	1,938	-	-	-	-	-	-	-	-	-	-
S&GA Expenses	3.3%	93.00	90.00	91.00	128	168	151	125	235	265	283	309	-	-	-	-	-	-	-	-	-	-
R&D Expenses	25.6%	476	379	413	402	377	401	425	1,214	534	692	593	-	-	-	-	-	-	-	-	-	-
Net Income	11.3%	-509	-574	-734	6,433	-996	-898	-1,021	-3,180	-1,572	-1,962	1,848	-	-	-	-	-	-	-	-	-	-
Net Income Margin	-	22.19*	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-Infinity%	-796	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-31.8%	4,905	7,195	8,982	1,251	2,438	3,511	4,317	5,359	6,265	7,633	8,607	9,628	10,606	11,473	12,213	13,333	1,096	1,974	3,055	839	688
Current Assets	-32.1%	4,868	7,169	8,945	1,206	2,379	3,428	4,224	5,231	6,105	7,419	8,312	9,280	10,229	11,114	11,917	12,815	718	1,440	2,506	262	314
Cash Equivalents	-34.8%	4,492	6,888	8,774	1,003	2,312	3,241	3,898	4,839	6,113	7,078	7,970	8,953	9,885	10,764	11,570	12,478	476	1,279	2,332	85.00	150
Inventory	-	-	-	-	-	-	-	-	-	-	288	285	279	284	281	253	225	184	139	130	157	171
Net PPE	58.8%	27.00	17.00	27.00	35.00	40.00	44.00	49.00	60.00	69.00	71.00	117	133	149	148	125	133	134	145	141	147	150
Liabilities	4.3%	1,708	1,638	1,239	1,240	1,208	1,156	1,127	1,128	1,110	1,132	1,321	1,479	1,624	1,526	1,791	2,386	2,508	2,836	3,040	3,525	3,561
Current Liabilities	4.0%	1,512	1,454	1,050	1,047	1,013	965	935	916	883	898	1,085	1,248	1,345	1,319	1,573	1,984	2,272	2,440	2,628	3,096	3,222
Shareholder's Equity	-42.5%	3,197	5,557	7,743	11.00	1,230	2,355	3,190	4,231	5,155	6,501	7,286	8,149	8,982	9,946	10,422	10,947	-	-	15.00	-	-
Retained Earnings	-2.2%	-109,853	-107,441	-105,218	-103,187	-101,901	-100,614	-99,686	-98,559	-97,466	-95,960	-95,156	-94,303	-93,399	-92,519	-92,010	-91,436	-90,703	-90,104	-89,107	-88,208	-87,186
Additional Paid-In Capital	0.0%	112,966	112,944	112,918	103,156	103,095	102,906	102,821	102,763	102,612	102,417	102,223	102,214	102,351	102,118	102,053	101,978	89,005	88,945	88,823	85,245	84,008
Shares Outstanding	0%	20,892	20,892	20,892	15,504	15,501	15,474	15,474	15,462	15,470	15,449	-	15,444,697	-	14,947,139	15,425,005	-	-	-	-	-	-
Float	-	-	-	5,363	-	-	-	3,930	-	-	-	32,694	-	-	-	48,840	-	-	-	48,584	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-28.2%	-2,411	-1,880	-954	-1,313	-940	-608	-916	-1,265	-973	-894	-969	-933	-844	-765	-903	-989	-796	-1,061	-1,220	-821	-1,089
Share Based Compensation	-32.3%	21.00	31.00	172	57.00	165	76.00	47.00	151	157	8.00	9.00	49.00	-	9.00	11.00	2.00	-95.77	122	152	179	-871
Cashflow From Investing	-	-	-	-	-	5.00	-	-	-	-4.00	-	-	-	-7.00	-31.00	-	-15.00	-446*	-12.64	-3.53	-6.38	8.00
Cashflow From Financing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	13,009	-574*	-	3,442	756	256

GCTK Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Research and development expenses (Note 6)	$ 4,704	$ 1,967
Marketing expenses	122
General and administrative expenses (Note 7)	2,278	2,465
Total operating expenses	7,104	4,432
Operating loss	7,104	4,432
Other expense		14
Finance income, net	(7)	(11)
Loss for the year	7,097	4,435
Other comprehensive loss (income):
Foreign currency translation adjustment	1	(23)
Comprehensive loss for the year	$ 7,098	$ 4,412
Basic loss per share	$ 0.38	$ 0.29
Diluted loss per share	$ 0.38	$ 0.29
Weighted average number of common stock outstanding used in computing basic net loss per share	20,760,266	15,474,600
Weighted average number of common stock outstanding used in computing diluted net loss per share	20,760,266	15,474,600

GCTK Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current Assets
Cash and cash equivalents (Note 2D)	$ 4,492	$ 2,312
Other current assets	376	67
Total current assets	4,868	2,379
Property and equipment, net	27	40
Restricted cash (Note 2D)	10	19
TOTAL ASSETS	4,905	2,438
Current Liabilities
Accounts payable	839	672
Other current liabilities	673	341
Total current liabilities	1,512	1,013
Non-current Liabilities
Loans from stockholders (Note 3)	196	195
Total liabilities	1,708	1,208
Commitments and contingent liabilities (Note 4)
Stockholders’ Equity (Note 5)
Common Stock of $ 0.001 par value (“Common Stock”): 500,000,000 shares authorized as of December 31, 2023 and 2022; 20,892,193 and 15,500,730 shares issued and outstanding as of December 31, 2023 and 2022, respectively	20	15
Additional paid-in capital	112,966	103,095
Receipts on account of shares	48	4
Accumulated other comprehensive income	16	17
Accumulated deficit	(109,853)	(101,901)
Total stockholders’ equity	3,197	1,230
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 4,905	$ 2,438

About GlucoTrack, Inc.

GlucoTrack, Inc., a medical device company, focuses on designing, developing, and commercializing non-invasive glucose monitoring devices for use by people with diabetes in the United States. It develops GlucoTrack, a non-invasive blood glucose monitor that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel.

WEBSITE	https://glucotrack.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	3

GlucoTrack, Inc. Frequently Asked Questions

What is the ticker symbol for GlucoTrack, Inc.? What does GCTK stand for in stocks?

GCTK is the stock ticker symbol of GlucoTrack, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of GlucoTrack, Inc. (GCTK)?

As of Tue Apr 23 2024, market cap of GlucoTrack, Inc. is 20.33 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GCTK stock?

You can check GCTK's fair value in chart for subscribers.

What is the fair value of GCTK stock?

You can check GCTK's fair value in chart for subscribers. The fair value of GlucoTrack, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of GlucoTrack, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for GCTK so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is GlucoTrack, Inc. a good stock to buy?

The fair value guage provides a quick view whether GCTK is over valued or under valued. Whether GlucoTrack, Inc. is cheap or expensive depends on the assumptions which impact GlucoTrack, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GCTK.

What is GlucoTrack, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, GCTK's PE ratio (Price to Earnings) is -2.87 and Price to Sales (PS) ratio is 105.48. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GCTK PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on GlucoTrack, Inc.'s stock?

In the past 10 years, GlucoTrack, Inc. has provided -0.387 (multiply by 100 for percentage) rate of return.